Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 4/20 | 0.47 |
| ▸ | PHF8 | Q9UPP1 | 4/20 | 0.47 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.47 |
| ▸ | KDM4A | O75164 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 4/20 | 0.42 |
| ▸ | CTSL | P07711 | 3/20 | 0.42 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 7/20 | 0.38 |
| ▸ | CTSS | P25774 | 4/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6873764 | 0.83 | CTSB (0.45) | KDM5APHF8KDM2AKDM4CKDM4A | |
| SCHEMBL5527651 | 0.81 | KDM5A (0.46) | KDM5APHF8KDM2AKDM4CKDM4A | |
| SCHEMBL5533909 | 0.76 | CTSK (0.50) | CTSBCTSLCTSKCTSSEPHX1 | |
| SCHEMBL6875724 | 0.75 | CTSK (0.52) | CTSBCTSLCTSKCTSS | |
| SCHEMBL6874659 | 0.75 | CTSK (0.40) | CTSBCTSLCTSKCTSSALDH1A1 | |
| SCHEMBL5526083 | 0.73 | CTSK (0.45) | CTSBCTSLCTSKCTSS | |
| SCHEMBL5534174 | 0.73 | CTSK (0.40) | CTSBCTSLCTSKCTSSEPHX2 | |
| SCHEMBL5526362 | 0.72 | ALDH1A1 (0.43) | CTSBCTSLCTSKCTSSHPGD | |
| SCHEMBL5528481 | 0.71 | CTSS (0.47) | CTSBCTSLCTSKCTSSALDH1A1 | |
| SCHEMBL8814416 | 0.70 | KDM5A (0.61) | KDM5APHF8KDM2AKDM4CKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015755-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| EP-1452522-A2 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040147745-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | US | disclosed |
| EP-1178958-B1 | N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS | AXYS PHARM INC (US) | 2004-02-18 | — | — | EP | disclosed |
| US-6455502-B1 | Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147745-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | KDM5A 1890/4885PHF8 2307/4885KDM2A 1741/4885 |
| US-20070015755-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | CTRL, SERPINB1, CPN1 | KDM5A 1890/4885PHF8 2307/4885KDM2A 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.